Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia

Summary

To date, there is no efficient therapeutics to prevent or treat COVID-19 related pulmonary failure. Corticosteroids (CS) could be a helpful therapeutic. Retrospective reports suggested survival improvement in patients with acute respiratory distress syndrome (ARDS). CT scan for COVID19 hospitalized patients showed sometimes unusual aspects of pneumonia, suggestive of an organizing phase of diffuse alveolar damage (DAD).

We hypothesize that, in the context of alveolar aggression induced by COVID-19, CT scan could help to individualize patients with a high probability of pulmonary organizing process who could benefit from CS treatment.

Conditions

• COVID-19

Interventions

DRUG

Prednisone

prednisone 0.7 mg/kg/d (PO)

DRUG

Hydrocortisone

hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)

Sponsors & Collaborators

• University Hospital, Tours

  lead OTHER

Principal Investigators

• LOUIS BERNARD, MD, PhD · CHRU DE TOURS

• JOUNEAU STEPHANE, MD, PhD · Rennes University Hospital

• MAILLOT FRANCOIS, MD · CHRU DE TOURS

• LIOGER BERTRAND, MD · CH DE BLOIS

• GOUPIL FRANCOIS, MD · CH Le Mans

• RABUT Thi- Tuyet Hong, MD · CH DE CHARTRES

• POPA Mihai, MD · CH DE RDREUX

• MOREL HUGUES, MD · CHR ORLEANS

• GUY TIPHAINE, MD · CH DE VANNES

• LEMMENS BRUNO, MD · CH AMBOISE

• BAZIN YANN, MD · CH SAINT MALO

• ROY XAVIER, MD · CH DE CHATEAUROUX

• PECQUERIAUX OLIVIER, MD · CH DE BOURGES

• MARCHAND ADAM Sylvain, MD, PhD · CHRU DE TOURS

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-03

Primary Completion

2020-07-03

Completion

2020-07-03